GLUE
Monte Rosa Therapeutics, Inc.
Key Financials
Net Income
$-38626000
↑ 46.9%
Operating Income
$-54208000
↑ 33.2%
Total Assets
$448.7M
↑ 2.3%
Total Liabilities
$215.6M
↓ 0.1%
Shareholders' Equity
$233.1M
↑ 4.5%
Cash & Equivalents
$129.9M
↓ 42.1%
Operating Cash Flow
$-22798000.00
↓ 154.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/7/2026 | View on SEC |
| 8-K | 5/7/2026 | View on SEC |
| 4 | 5/5/2026 | View on SEC |
| 144 | 5/1/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEFA14A | 4/29/2026 | View on SEC |
| DEF 14A | 4/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | GLUE |
| Company Name | Monte Rosa Therapeutics, Inc. |
| CIK | 1826457 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 617-949-2643 |